SHAREHOLDER ALERT: BLU UAVS KDMN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / April 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
BELLUS Health Inc. (NASDAQ:BLU)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/bellus-health-inc-investigation-loss-submission-form?prid=14816&wire=1
Lead Plaintiff Deadline: May 17, 2021
Class Period: September 5, 2019 - July 5, 2020
Allegations against BLU include that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.
AgEagle Aerial Systems, Inc. (NYSE:UAVS)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/ageagle-aerial-systems-inc-loss-submission-form?prid=14816&wire=1
Lead Plaintiff Deadline: April 27, 2021
Class Period: September 3, 2019 - February 18, 2021
Allegations against UAVS include that: (1) AgEagle did not have a partnership with Amazon and in fact never had any relationship with Amazon; (2) rather than correct the public's understanding about a partnership with Amazon, Defendants were actively contributing to the rumor that AgEagle had a partnership with Amazon; and (3) as a result, Defendants' statements about AgEagle's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Kadmon Holdings, Inc. (NASDAQ:KDMN)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/kadmon-holdings-inc-loss-submission-form?prid=14816&wire=1
Lead Plaintiff Deadline: June 2, 2021
Class Period: October 1, 2020 - March 10, 2021
Allegations against KDMN include that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/641047/SHAREHOLDER-ALERT-BLU-UAVS-KDMN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
